Prospective study of the UGT1A127 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)
Background Uridine 5′‐diphospho‐glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study. Met...
Gespeichert in:
| Veröffentlicht in: | Thoracic cancer 2016-07, Vol.7 (4), p.467-472 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 472 |
|---|---|
| container_issue | 4 |
| container_start_page | 467 |
| container_title | Thoracic cancer |
| container_volume | 7 |
| creator | Fukuda, Minoru Suetsugu, Takayuki Shimada, Midori Kitazaki, Takeshi Hashiguchi, Kohji Kishimoto, Junji Harada, Taishi Seto, Takashi Ebi, Noriyuki Takayama, Koichi Sugio, Kenji Semba, Hiroshi Nakanishi, Yoichi Ichinose, Yukito |
| description | Background
Uridine 5′‐diphospho‐glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study.
Methods
Eligibility criteria included: lung cancer patients; scheduled irinotecan therapy doses of single ≥ 80, combination ≥ 50, radiation with single ≥ 50, or radiation with combination ≥ 40 mg/m2; age ≥ 20; and Eastern Cooperative Oncology Group performance score (PS) 0–2. Patients were examined for UGT1A1*28 and *6 polymorphisms and received irinotecan. When the UGT1A1*28 polymorphism was detected, a search for UGT1A1*27 was conducted. Fifty patients were enrolled, with 48 patients determined eligible.
Results
UGT1A1 polymorphisms *28/*28, *6/*6, *28/*6, *28/−, *6/−, −/− observed 0 (0%), 1 (2%), 1 (2%), 7 (15%), 17 (35%) and 22 (46%), respectively. UGT1A1*27 were examined in nine patients including one ineligible patient; however, no polymorphisms were found. The study ceased after interim analysis. In an evaluation of the side effects of irinotecan, patients with UGT1A1*28 and UGT1A1*6 polymorphisms had a higher tendency to experience febrile neutropenia than wild type (25% and 32% vs. 14%). Incidences of grade 3/4 leukopenia and neutropenia were significantly higher in patients with UGT1A1*28 polymorphisms compared with wild type (75% vs. 32%, P = 0.049; 75% vs. 36%, P = 0.039, respectively).
Conclusion
Our prospective study did not locate the UGT1A1*27 polymorphism, suggesting that UGT1A1*27 does not significantly predict severe irinotecan toxicity in cancer patients. |
| doi_str_mv | 10.1111/1759-7714.12360 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4930967</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A737058432</galeid><sourcerecordid>A737058432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6480-a11b95c545cebbaf0b11e4a04994cd83764cf9293a88979d70993c2cdcda38033</originalsourceid><addsrcrecordid>eNqFkl-L1DAUxYso7rLus28S8GV9mNn8aZrGB2EcdJQdWJHZ55CmaSdLm9Sk2aUfx29q6qyjK4IpNOXmd87lpifLXiK4RGldIkb5gjGULxEmBXySnR4rT4_fsDjJzkO4hWmRkkNMn2cnmJGScg5Ps-9fvAuDVqO50yCMsZ6Aa8C41-Bms0MrhBlotdVgcN3UOz_sTehBHb2xLTDp7UatpJ0FXg4TMBYMcjTajgHcm3EPupjARCjt34KvOsQunaQO27l-bZXrXDuBjXdxmMVXUwxTBBfb683nKwRh_v7Ni-xZI7ugzx_2s-zm44fd-tNiZtar7UIVeQkXEqGKU0VzqnRVyQZWCOlcwpzzXNUlYUWuGo45kWXJGa8Z5JworGpVS1JCQs6ydwffIVa9rlWawctODN700k_CSSMen1izF627EzknkBcsGVw8GHj3Leowit4EpbtOWu1iEKiE6d4Jpzihr_9Cb130No0nMOYQEUwx_U21stPC2Malvmo2FStGGKRlTmav5T-o9NS6N8pZ3ZhUfyS4PAhU-vXB6-Y4I4JiDpaYoyPmGImfwUqKV39ezZH_FaME0ANwn3pN__MTu_XqYPwDWdnWuw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290132525</pqid></control><display><type>article</type><title>Prospective study of the UGT1A127 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)</title><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Fukuda, Minoru ; Suetsugu, Takayuki ; Shimada, Midori ; Kitazaki, Takeshi ; Hashiguchi, Kohji ; Kishimoto, Junji ; Harada, Taishi ; Seto, Takashi ; Ebi, Noriyuki ; Takayama, Koichi ; Sugio, Kenji ; Semba, Hiroshi ; Nakanishi, Yoichi ; Ichinose, Yukito</creator><creatorcontrib>Fukuda, Minoru ; Suetsugu, Takayuki ; Shimada, Midori ; Kitazaki, Takeshi ; Hashiguchi, Kohji ; Kishimoto, Junji ; Harada, Taishi ; Seto, Takashi ; Ebi, Noriyuki ; Takayama, Koichi ; Sugio, Kenji ; Semba, Hiroshi ; Nakanishi, Yoichi ; Ichinose, Yukito</creatorcontrib><description>Background
Uridine 5′‐diphospho‐glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study.
Methods
Eligibility criteria included: lung cancer patients; scheduled irinotecan therapy doses of single ≥ 80, combination ≥ 50, radiation with single ≥ 50, or radiation with combination ≥ 40 mg/m2; age ≥ 20; and Eastern Cooperative Oncology Group performance score (PS) 0–2. Patients were examined for UGT1A1*28 and *6 polymorphisms and received irinotecan. When the UGT1A1*28 polymorphism was detected, a search for UGT1A1*27 was conducted. Fifty patients were enrolled, with 48 patients determined eligible.
Results
UGT1A1 polymorphisms *28/*28, *6/*6, *28/*6, *28/−, *6/−, −/− observed 0 (0%), 1 (2%), 1 (2%), 7 (15%), 17 (35%) and 22 (46%), respectively. UGT1A1*27 were examined in nine patients including one ineligible patient; however, no polymorphisms were found. The study ceased after interim analysis. In an evaluation of the side effects of irinotecan, patients with UGT1A1*28 and UGT1A1*6 polymorphisms had a higher tendency to experience febrile neutropenia than wild type (25% and 32% vs. 14%). Incidences of grade 3/4 leukopenia and neutropenia were significantly higher in patients with UGT1A1*28 polymorphisms compared with wild type (75% vs. 32%, P = 0.049; 75% vs. 36%, P = 0.039, respectively).
Conclusion
Our prospective study did not locate the UGT1A1*27 polymorphism, suggesting that UGT1A1*27 does not significantly predict severe irinotecan toxicity in cancer patients.</description><identifier>ISSN: 1759-7706</identifier><identifier>EISSN: 1759-7714</identifier><identifier>DOI: 10.1111/1759-7714.12360</identifier><identifier>PMID: 27385990</identifier><language>eng</language><publisher>Melbourne: John Wiley & Sons Australia, Ltd</publisher><subject>Analysis ; Angina pectoris ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Diarrhea ; Drug dosages ; Gene polymorphism ; Genetic aspects ; Genetic polymorphisms ; Genetic research ; Haplotypes ; irinotecan ; Lung cancer ; Neutropenia ; Oncology ; Oncology, Experimental ; Original ; Patients ; Polymorphism ; prospective ; Studies ; UGT1A1</subject><ispartof>Thoracic cancer, 2016-07, Vol.7 (4), p.467-472</ispartof><rights>2016 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd</rights><rights>COPYRIGHT 2016 John Wiley & Sons, Inc.</rights><rights>2016. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6480-a11b95c545cebbaf0b11e4a04994cd83764cf9293a88979d70993c2cdcda38033</citedby><cites>FETCH-LOGICAL-c6480-a11b95c545cebbaf0b11e4a04994cd83764cf9293a88979d70993c2cdcda38033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930967/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930967/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27385990$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fukuda, Minoru</creatorcontrib><creatorcontrib>Suetsugu, Takayuki</creatorcontrib><creatorcontrib>Shimada, Midori</creatorcontrib><creatorcontrib>Kitazaki, Takeshi</creatorcontrib><creatorcontrib>Hashiguchi, Kohji</creatorcontrib><creatorcontrib>Kishimoto, Junji</creatorcontrib><creatorcontrib>Harada, Taishi</creatorcontrib><creatorcontrib>Seto, Takashi</creatorcontrib><creatorcontrib>Ebi, Noriyuki</creatorcontrib><creatorcontrib>Takayama, Koichi</creatorcontrib><creatorcontrib>Sugio, Kenji</creatorcontrib><creatorcontrib>Semba, Hiroshi</creatorcontrib><creatorcontrib>Nakanishi, Yoichi</creatorcontrib><creatorcontrib>Ichinose, Yukito</creatorcontrib><title>Prospective study of the UGT1A127 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)</title><title>Thoracic cancer</title><addtitle>Thorac Cancer</addtitle><description>Background
Uridine 5′‐diphospho‐glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study.
Methods
Eligibility criteria included: lung cancer patients; scheduled irinotecan therapy doses of single ≥ 80, combination ≥ 50, radiation with single ≥ 50, or radiation with combination ≥ 40 mg/m2; age ≥ 20; and Eastern Cooperative Oncology Group performance score (PS) 0–2. Patients were examined for UGT1A1*28 and *6 polymorphisms and received irinotecan. When the UGT1A1*28 polymorphism was detected, a search for UGT1A1*27 was conducted. Fifty patients were enrolled, with 48 patients determined eligible.
Results
UGT1A1 polymorphisms *28/*28, *6/*6, *28/*6, *28/−, *6/−, −/− observed 0 (0%), 1 (2%), 1 (2%), 7 (15%), 17 (35%) and 22 (46%), respectively. UGT1A1*27 were examined in nine patients including one ineligible patient; however, no polymorphisms were found. The study ceased after interim analysis. In an evaluation of the side effects of irinotecan, patients with UGT1A1*28 and UGT1A1*6 polymorphisms had a higher tendency to experience febrile neutropenia than wild type (25% and 32% vs. 14%). Incidences of grade 3/4 leukopenia and neutropenia were significantly higher in patients with UGT1A1*28 polymorphisms compared with wild type (75% vs. 32%, P = 0.049; 75% vs. 36%, P = 0.039, respectively).
Conclusion
Our prospective study did not locate the UGT1A1*27 polymorphism, suggesting that UGT1A1*27 does not significantly predict severe irinotecan toxicity in cancer patients.</description><subject>Analysis</subject><subject>Angina pectoris</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Diarrhea</subject><subject>Drug dosages</subject><subject>Gene polymorphism</subject><subject>Genetic aspects</subject><subject>Genetic polymorphisms</subject><subject>Genetic research</subject><subject>Haplotypes</subject><subject>irinotecan</subject><subject>Lung cancer</subject><subject>Neutropenia</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Original</subject><subject>Patients</subject><subject>Polymorphism</subject><subject>prospective</subject><subject>Studies</subject><subject>UGT1A1</subject><issn>1759-7706</issn><issn>1759-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkl-L1DAUxYso7rLus28S8GV9mNn8aZrGB2EcdJQdWJHZ55CmaSdLm9Sk2aUfx29q6qyjK4IpNOXmd87lpifLXiK4RGldIkb5gjGULxEmBXySnR4rT4_fsDjJzkO4hWmRkkNMn2cnmJGScg5Ps-9fvAuDVqO50yCMsZ6Aa8C41-Bms0MrhBlotdVgcN3UOz_sTehBHb2xLTDp7UatpJ0FXg4TMBYMcjTajgHcm3EPupjARCjt34KvOsQunaQO27l-bZXrXDuBjXdxmMVXUwxTBBfb683nKwRh_v7Ni-xZI7ugzx_2s-zm44fd-tNiZtar7UIVeQkXEqGKU0VzqnRVyQZWCOlcwpzzXNUlYUWuGo45kWXJGa8Z5JworGpVS1JCQs6ydwffIVa9rlWawctODN700k_CSSMen1izF627EzknkBcsGVw8GHj3Leowit4EpbtOWu1iEKiE6d4Jpzihr_9Cb130No0nMOYQEUwx_U21stPC2Malvmo2FStGGKRlTmav5T-o9NS6N8pZ3ZhUfyS4PAhU-vXB6-Y4I4JiDpaYoyPmGImfwUqKV39ezZH_FaME0ANwn3pN__MTu_XqYPwDWdnWuw</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>Fukuda, Minoru</creator><creator>Suetsugu, Takayuki</creator><creator>Shimada, Midori</creator><creator>Kitazaki, Takeshi</creator><creator>Hashiguchi, Kohji</creator><creator>Kishimoto, Junji</creator><creator>Harada, Taishi</creator><creator>Seto, Takashi</creator><creator>Ebi, Noriyuki</creator><creator>Takayama, Koichi</creator><creator>Sugio, Kenji</creator><creator>Semba, Hiroshi</creator><creator>Nakanishi, Yoichi</creator><creator>Ichinose, Yukito</creator><general>John Wiley & Sons Australia, Ltd</general><general>John Wiley & Sons, Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201607</creationdate><title>Prospective study of the UGT1A127 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)</title><author>Fukuda, Minoru ; Suetsugu, Takayuki ; Shimada, Midori ; Kitazaki, Takeshi ; Hashiguchi, Kohji ; Kishimoto, Junji ; Harada, Taishi ; Seto, Takashi ; Ebi, Noriyuki ; Takayama, Koichi ; Sugio, Kenji ; Semba, Hiroshi ; Nakanishi, Yoichi ; Ichinose, Yukito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6480-a11b95c545cebbaf0b11e4a04994cd83764cf9293a88979d70993c2cdcda38033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analysis</topic><topic>Angina pectoris</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Diarrhea</topic><topic>Drug dosages</topic><topic>Gene polymorphism</topic><topic>Genetic aspects</topic><topic>Genetic polymorphisms</topic><topic>Genetic research</topic><topic>Haplotypes</topic><topic>irinotecan</topic><topic>Lung cancer</topic><topic>Neutropenia</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Original</topic><topic>Patients</topic><topic>Polymorphism</topic><topic>prospective</topic><topic>Studies</topic><topic>UGT1A1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fukuda, Minoru</creatorcontrib><creatorcontrib>Suetsugu, Takayuki</creatorcontrib><creatorcontrib>Shimada, Midori</creatorcontrib><creatorcontrib>Kitazaki, Takeshi</creatorcontrib><creatorcontrib>Hashiguchi, Kohji</creatorcontrib><creatorcontrib>Kishimoto, Junji</creatorcontrib><creatorcontrib>Harada, Taishi</creatorcontrib><creatorcontrib>Seto, Takashi</creatorcontrib><creatorcontrib>Ebi, Noriyuki</creatorcontrib><creatorcontrib>Takayama, Koichi</creatorcontrib><creatorcontrib>Sugio, Kenji</creatorcontrib><creatorcontrib>Semba, Hiroshi</creatorcontrib><creatorcontrib>Nakanishi, Yoichi</creatorcontrib><creatorcontrib>Ichinose, Yukito</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Thoracic cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fukuda, Minoru</au><au>Suetsugu, Takayuki</au><au>Shimada, Midori</au><au>Kitazaki, Takeshi</au><au>Hashiguchi, Kohji</au><au>Kishimoto, Junji</au><au>Harada, Taishi</au><au>Seto, Takashi</au><au>Ebi, Noriyuki</au><au>Takayama, Koichi</au><au>Sugio, Kenji</au><au>Semba, Hiroshi</au><au>Nakanishi, Yoichi</au><au>Ichinose, Yukito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospective study of the UGT1A127 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)</atitle><jtitle>Thoracic cancer</jtitle><addtitle>Thorac Cancer</addtitle><date>2016-07</date><risdate>2016</risdate><volume>7</volume><issue>4</issue><spage>467</spage><epage>472</epage><pages>467-472</pages><issn>1759-7706</issn><eissn>1759-7714</eissn><abstract>Background
Uridine 5′‐diphospho‐glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study.
Methods
Eligibility criteria included: lung cancer patients; scheduled irinotecan therapy doses of single ≥ 80, combination ≥ 50, radiation with single ≥ 50, or radiation with combination ≥ 40 mg/m2; age ≥ 20; and Eastern Cooperative Oncology Group performance score (PS) 0–2. Patients were examined for UGT1A1*28 and *6 polymorphisms and received irinotecan. When the UGT1A1*28 polymorphism was detected, a search for UGT1A1*27 was conducted. Fifty patients were enrolled, with 48 patients determined eligible.
Results
UGT1A1 polymorphisms *28/*28, *6/*6, *28/*6, *28/−, *6/−, −/− observed 0 (0%), 1 (2%), 1 (2%), 7 (15%), 17 (35%) and 22 (46%), respectively. UGT1A1*27 were examined in nine patients including one ineligible patient; however, no polymorphisms were found. The study ceased after interim analysis. In an evaluation of the side effects of irinotecan, patients with UGT1A1*28 and UGT1A1*6 polymorphisms had a higher tendency to experience febrile neutropenia than wild type (25% and 32% vs. 14%). Incidences of grade 3/4 leukopenia and neutropenia were significantly higher in patients with UGT1A1*28 polymorphisms compared with wild type (75% vs. 32%, P = 0.049; 75% vs. 36%, P = 0.039, respectively).
Conclusion
Our prospective study did not locate the UGT1A1*27 polymorphism, suggesting that UGT1A1*27 does not significantly predict severe irinotecan toxicity in cancer patients.</abstract><cop>Melbourne</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>27385990</pmid><doi>10.1111/1759-7714.12360</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1759-7706 |
| ispartof | Thoracic cancer, 2016-07, Vol.7 (4), p.467-472 |
| issn | 1759-7706 1759-7714 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4930967 |
| source | Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Analysis Angina pectoris Cancer Cancer therapies Care and treatment Chemotherapy Diarrhea Drug dosages Gene polymorphism Genetic aspects Genetic polymorphisms Genetic research Haplotypes irinotecan Lung cancer Neutropenia Oncology Oncology, Experimental Original Patients Polymorphism prospective Studies UGT1A1 |
| title | Prospective study of the UGT1A127 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T22%3A04%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospective%20study%20of%20the%20UGT1A127%20gene%20polymorphism%20during%20irinotecan%20therapy%20in%20patients%20with%20lung%20cancer:%20Results%20of%20Lung%20Oncology%20Group%20in%20Kyusyu%20(LOGIK1004B)&rft.jtitle=Thoracic%20cancer&rft.au=Fukuda,%20Minoru&rft.date=2016-07&rft.volume=7&rft.issue=4&rft.spage=467&rft.epage=472&rft.pages=467-472&rft.issn=1759-7706&rft.eissn=1759-7714&rft_id=info:doi/10.1111/1759-7714.12360&rft_dat=%3Cgale_pubme%3EA737058432%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2290132525&rft_id=info:pmid/27385990&rft_galeid=A737058432&rfr_iscdi=true |